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Abstract
Aims: To compare the effectiveness and safety of polypropylene (PP) and
polyvinylidene fluoride (PVDF) transobturator tapes (TOT) for the treatment
of female stress urinary incontinence (SUI).
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Methods: This is a multicentre randomized trial. Women with SUI or stress‐
predominant mixed urinary incontinence and scheduled for a TOT procedure
were randomized to PP or PVDF slings. The primary outcome was 1‐year cure
or improvement rate using composite criteria. Complications were also com-
pared. Relationships with outcomes were analyzed using multivariable logistic
regressions models.
Results: From April 2016 to January 2018 285 participants were randomized.
PP and PVDF slings showed similar high cure or improvement rate (91.0% vs.
95.6%, p= .138). Improvement in validated questionnaires was also similar. PVDF
slings were associated with a lower rate of de novo urgency incontinence (adjusted
odds ratio= 0.35; 95% confidence interval = 0.15–0.80). We found no statistical
differences in complications rates, although a higher incidence of long‐term pain
events were observed in the PP group. The study is underpowered to find differ-
ences in specific complications owing to the low number of events.
Conclusion: PP and PVDF TOTs are equally effective, although PVDF is
associated with fewer cases of de novo urgency incontinence. Further studies
are needed to give robust conclusions on safety profiles.
KEYWORD S
de novo urgency incontinence, midurethral sling, polypropylene, polyvinylidene fluoride,
PVDF, sling complications, stress urinary incontinence, suburethral sling, suburethral tape,
transobturator
1 | INTRODUCTION
One of the most common first line surgical treatments for
female stress urinary incontinence (SUI) is currently the
use of tension‐free suburethral tapes. Both retropubic and
transobturator routes have shown a similarly high
effectiveness but with different complication profiles.1–5
Specifically, complication rates for transobturator tapes
(TOT) ranged from 11% to 31%.6 It is well known that
biomechanical and biocompatibility properties of the
materials used in the slings are related to their success
and complication rates.7–10 Therefore, some of the com-
plications that could be related to the sling's material,
such as de novo urgency incontinence (UUI), pain, sling
extrusion and voiding dysfunction may be further
decreased by improving this material.
Although many brands have developed their own slings,
the synthetic material utilized in these tapes is mainly poly-
propylene (PP). However, the use of polyvinylidene fluoride
(PVDF) in suburethral tapes is also approved in Europe.
PVDF is a nonabsorbable fluoropolymer introduced in 2002
for surgical meshes 11 with improved biocompatibility in
animal studies.12,13 Some of its biomechanical properties are
lower elongation and deformation capacities compared with
PP.14 These characteristics are the basis to hypothesize that
PVDF slings may be associated with less mesh‐related
complications.
In a previous descriptive clinical study we found si-
milar effectiveness and complications with PP and PVDF
slings, although more obstructive events were observed in
the PP group.15 However, to date there are no clinical
trials comparing those materials in suburethral slings. For
that reason we designed this randomized controlled trial
(RCT) to establish whether PP and PVDF TOTs are
equally effective for treating female SUI. Secondarily,
safety profiles will be compared.
2 | MATERIALS AND METHODS
The present study was designed as a pragmatic, multi-
centre RCT to compare the effectiveness of PP and PVDF
TOTs for the treatment of female SUI. Eleven Spanish
hospitals were initially included in the trial. The research
protocol was approved by the Ethics Committee of the
participating centers or explicitly accepted the approval of
the coordinating center in the absence of an own ethics
committee. The protocol was registered at the public
registry ClinicalTrials. gov (NCT02886520).
Patients attending at the participant hospitals because of
SUI or stress‐predominant mixed urinary incontinence
(MUI) were considered for participation in the study.
Exclusion criteria were previous continence surgery with
midurethral slings, the presence of MUI with predominant
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urgency incontinence, intrinsic sphincter deficiency (de-
fined as maximal urethral closure pressure of 20 cmH2O or
less or as Valsalva leak point pressure of 60 cmH2O or less)
when it was evaluable, the existence of neurogenic bladder,
the incapacity to understand the information or to give
their consent, and age less than 18 years. Women were
regarded eligible if they met the inclusion and exclusion
criteria. All women received a detailed explanation about
the surgical procedure and the study, and written informed
consent was obtained.
Preoperative evaluation included a detailed physical
examination including a cough stress test (patients were
invited to attend follow‐up visits at least 2 h after the last
micturition), an interview following a questionnaire with
signs and symptoms of lower urinary tract dysfunction
based on the terminology recommended by the Interna-
tional Continence Society,16 a urinalysis and urine cul-
ture. SUI was diagnosed clinically by the cough stress test
in all cases. Pelvic organ prolapse (POP) was staged using
the POP‐Q system. Preoperative urodynamic study before
surgery was optional according to each center's protocol.
Participants also completed preoperatively the Sandvik's
incontinence severity index validated for Spanish
language and that categorizes incontinence into four
groups (a fifth group was defined for zero punctuation
that means no‐incontinence)17 and the International
Consultation on Incontinence Questionnaire‐Short Form
(ICIQ‐SF).
A block‐randomization procedure, stratified by cen-
ter, was carried out using a random number generator
program. Allocation was performed in a 1:1 ratio.
Randomization sequence was concealed in a centralized
electronic website designed specifically for this study
(http://www.ribk.com/C3PO/). Group assignment was
performed before surgeries once participants agreed with
the study. Commercial kits of Amid Type‐I PP‐TOTs used
were those that each center used in their daily practice.
The second material studied in TOTs was PVDF
(DynaMesh‐SIS direct soft; FEG Textiltechnik). All the
procedures were performed by experienced surgeons
with experience of both types of sling material. Patients
were not blinded for the procedure. TOT procedures
were done following the standard technique18 and ac-
cording to the instructions of the different brands, in-
cluding the insertion routes. The tapes were placed
tension‐free without the aid of a cough test. PP and
PVDF slings were left under the midurethra in the same
manner, leaving a small distance between tape and ure-
thra by placing a scissor or a forceps between them.
Surgery for POP correction was associated when needed.
Postoperative follow‐up visits were scheduled at 1, 6
(optional), and 12 months. These included physical ex-
amination with a cough stress test in the same conditions
than in the preoperative evaluation and an interview
about symptoms of incontinence, use of urinary protec-
tion, micturition difficulties, pain in groins or thighs and
dyspareunia. Patient satisfaction was assessed with the
patient global impression of improvement (PGI‐I) ques-
tionnaire19 one year after surgery. Women also com-
pleted the Sandvik and ICIQ‐SF questionnaires at this
follow‐up point.
The primary outcome was the cure or improvement
rate one year after surgery, classified following a compo-
site objective and subjective criteria. Patients were re-
garded as cured if they had no stress leaks, the stress test
was negative and they were fully satisfied with the
operation (Sandvik and ICIQ‐SF scores = 0, PGI‐I = 1–2).
To be regarded as improved, the cough stress test had to
be negative and the patient moderately satisfied with the
result of surgery due to sporadic stress leaks or to an in-
crease in urinary frequency with or without sporadic UUI
episodes (Sandvik and ICIQ‐SF> 0, PGI = 2–3). Patients
were classified as failures in the presence of a positive
cough test and/or dissatisfaction with the surgery, in-
cluding de novo UUI and/or voiding dysfunction asso-
ciated with frequent urinary infections and the use of the
same urinary protection during daily activities as before
the surgery (PGI‐I≥ 4). Intraoperative and postopera-
tive complications were also recorded. Early postoperative
complications were defined as those that occurred within
the first month after surgery; late postoperative compli-
cations were those that were present greater than 1 month
after surgery. De novo urgency was diagnosed clinically by
the presence of new onset bothersome overactive bladder
symptoms or by worsening of previous ones. Elevated
post‐void residual volume was defined as a urine residual
of greater than 100ml measured by introital ultrasound or
by urethral catheterization.
Sample size calculation was based on the results of
our preliminary study with both materials15 and also
according to clinical relevance criterion. It was estimated
that 282 patients were needed to provide 80% power to
detect a 10% difference in success rate with an assumed
cure rate of 95% for the reference procedure and a two‐
sided α‐error of 0.05.
Statistical analysis was conducted by a third party not
involved in the study. Normal distribution for continuous
variables was assessed using the Shapiro–Wilk test.
Quantitative variables were compared using the unpaired
Student's t test and with the Mann–Whitney U test for
those variables that did not follow a normal distribution.
Categorical variables were analyzed using the χ2 test or
Fisher's exact test when indicated. Outcomes analyses
were performed on an intention‐to‐treat basis. A second
per‐protocol analysis for the primary outcome was pro-
jected. Univariate analyses were performed with each
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baseline variable by means of logistic regression. Multi-
variate logistic regression models were constructed for-
cing them to keep the sling material and using a forward
process based on the improvement of the likelihood and
the Akaike's criterion of the model with a p< .10 to de-
cide to include a new variable. Sensitivity for the primary
outcome was evaluated using a shrinkage coefficient to
calibrate the model. One prespecified subgroup analysis
was planned on women with detrussor underactivity.
Changes in quantitative variables within‐procedures
were analyzed by means of the Student's paired t test
and differences in the changes between‐procedures were
compared with the unpaired t test. A two‐tailed p< .05
was considered to indicate statistical significance for the
analyses cited hereinbefore and 95% confidence intervals
(CIs) were calculated. Analyses were conducted with the
software Stata version 15.1 (StataCorp) and SPSS version
18.0 (IBM).
3 | RESULTS
Between April 2016 and January 2018 a total of 307 pa-
tients were assessed for eligibility. One of the 11 parti-
cipating centers withdrew from the study before
including any participant. Patients' recruitment was
stopped once the estimated sample size was reached. Of
them, 285 patients underwent randomization during the
study period, but one withdrew her consent to the study
after having been randomized. Finally, 284 women were
suitable for the analysis, 140 in the PP group and 144 in
the PVDF one (Figure 1). Preoperative characteristics of
both groups were similar and are detailed in Table 1. In
the PP group the TOT was inserted via the outside‐in
route in 123 women, whereas in the remaining 16 pa-
tients the inside‐out route was used. All women in the
PVDF group underwent the TOT through the outside‐in
approach. At the time of the surgery 73 women (25.4%)
FIGURE 1 CONSORT flow diagram of the study. PP, polypropylene; PVDF, polyvinylidene fluoride
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underwent concomitant surgery for POP. During the
1‐year follow‐up period, 13 women (4.58%) were lost to
follow‐up.
3.1 | Primary outcome
On the intention‐to‐treat analysis the cure/improvement
rate was similar with both sling materials: PP 91%
(122/134) versus PVDF 95.6% (131/137, p= .138). In the
univariate analysis the presence of urge‐incontinence
before surgery was the only variable associated with a
failure of the procedure (odds ratio [OR] = 3.21, 95%
CI = 1.10–9.32). Concomitant POP surgery was not as-
sociated to failure (p= .785). Among failures (n = 18),
5 women (27.8%) underwent concomitant POP surgery
while 13 (72.2%) did not. However, in the final multi-
variate analysis the sling material was the only variable
included in the final model obtaining the same results
(PVDF OR= 0.47, 95% CI = 0.17–1.28). The failures
observed in the PP group were because of persistent SUI
in three cases, MUI in four cases, severe de novo urge
incontinence in four cases and voiding dysfunction in
one case. In the PVDF group 2 cases failed because of
persistent SUI and four cases because of MUI. Both the
ICIQ‐SF and Sandvik scores improved after surgery with
PP and PVDF slings. Subjective improvement, assessed
with these questionnaires and the PGI‐I, was similar in
both groups (Table 2). Calibrated model leads to a
shrinkage coefficient of 0.098 and therefore no correction
of the coefficients has been finally performed.
We conducted a per‐protocol analysis including
130 women in the PP group and 135 in the PVDF group.
Results were materially unchanged, with an OR of failure
in the PVDF group of 0.46 (95% CI = 0.17–1.26).
The subgroup analyses on patients with suspected
detrussor underactivity included only 33 women. The
observed results were similar to those on the whole study
population, with an OR of failure in the PVDF group of
0.25 (95% CI = 0.02–3.10).
3.2 | Complications
Complications are detailed in Table 3. Seven women
(5.1%) experienced an intraoperative complication in the
PP group and four (2.8%) in the PVDF group. The sling
material was not associated with intraoperative compli-
cations on the multivariate model (PVDF OR= 1.10, 95%
CI = 0.97–1.25) as any other variable either.
Early postoperative complications were observed in
25 women in the PP group (18.1%) and 22 in the PVDF
one (15.5%). In the multivariate analysis only the asso-
ciated surgery to the TOT procedure was related to these
complications (OR = 2.58, 95% CI = 1.26–5.28). Eight
women (5.71%) in the PP group experienced voiding
dysfunction with elevated post‐void residual volumes,
one of them requiring sling loosening in the first days
after surgery. In the PVDF group elevated post‐void re-
sidual volumes were present in 10 women (6.94%). One
case of very early sling vaginal exposure was present in
each group.
Late postoperative complications were recorded in 14
women (10.4%) in the PP group and 10 in the PVDF












Parityb 2 (2–3) 2 (2–3) .607
Vaginal deliveriesb 2 (2–3) 2 (2–3) .548
Menopausec 88 (62.9) 94 (65.3) .671
Smoking habitc .417
Nonsmoker 98 (71.5) 92 (65.3)
Former smoker 18 (13.1) 19 (13.5)
Current smoker 21 (15.3) 30 (21.3)
Urethral hypermobilityc 112 (80.6) 107 (77.0) .463
Sandvik scoreb 8 (8–12) 8 (8–12) .399
ICIQ‐SFb 16 (14–18) 16 (14–18) .332
Previous UUIc 61 (44.2) 51 (36.9) .430
Associated POPc 55 (39.3) 52 (36.4) .612
Associated surgeryc 34 (24.5) 39 (27.3) .590
Anterior repair 12 12
Manchester procedure 0 1





Posterior repair 0 3
Colpocleisis 1 2
Other surgeries 3 0
Abbreviations: BMI, body mass index; ICIQ‐SF, International Consultation
on Incontinence Questionnaire‐Short Form; PP, polypropylene; POP, pelvic
organ prolapse; PVDF, polyvinylidene fluoride; UUI, urinary
urge‐incontinence.
ap Value comparing groups characteristic.
bData expressed in median (interquartile range).
cData expressed in n (%).
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group (7.2%). Neither overall late complication rate
(PVDF OR= 0.64, 95% CI = 0.27–1.52) nor any specific
late complication was associated with sling material.
Finally, we find a lower rate of de novo UUI in the PVDF
group with an adjusted OR= 0.35 (95% CI = 0.15–0.80;
Table 3). Associated POP was not related to de novo UUI
(p= .456). Among women who suffered de novo UUI,
6 (27.3%) underwent associated POP surgery whereas 16
women (72.7%) did not in the PP group (p= .753). In the
PVDF group four women (40.0%) underwent associated
POP surgery and six (60.0%) did not (p= .458). Sling
division was needed in three patients in the PP group
(in 2 because of voiding dysfunction and in 1 because of
vaginal extrusion) while none in the PVDF group, how-
ever this difference was not significant (p= .121).
4 | DISCUSSION
There are no previous clinical trials comparing the ef-
fectiveness of PP and PVDF in midurethral slings for
treating female SUI. The present study finds similar ef-
fectiveness of both materials under the specified criteria.
The observed overall high success rates at 1 year are in
accordance with the results obtained in a previous ob-
servational study.15 However, no data are available on
long‐term outcomes comparing these materials.
Safety however, is also a major issue for surgical pro-
cedures. Safety of PVDF meshes in urogynecology has
been reported previously.15,20,21 In the present trial, we
TABLE 2 Questionnaires scores
Preoperative Postoperative p Within group
PP PVDF PP PVDF PP PVDF p Between groups
ICIQ‐SFa 16 (14–18) 16 (14–18) 0 (0–6) 0 (0–5) .000 .000 .149
Sandvika 8 (8–12) 8 (8–12) 0 (0–3.75) 0 (0–3) .000 .000 .173
No UI 4 (2.9%) 4 (2.8%) 72 (54.5%) 76 (55.9%)
Slight 3 (2.2%) 1 (0.7%) 20 (15.2%) 24 (17.6%)
Moderate 26 (19.0%) 23 (16.3%) 32 (24.2%) 32 (23.5%)
Severe 64 (46.7%) 66 (46.8%) 7 (5.3%) 3 (2.2%)
Very severe 40 (29.2%) 47 (33.3%) 1 (0.8%) 1 (0.8%)
PGI‐Ia 1 (1–2) 1 (1–2) .757
Very much/much better 115 (89.1%) 122 (91.7%)
Little better 7 (5.4%) 6 (4.5%)
No change or worse 7 (5.4%) 5 (3.8%)
Abbreviations: ICIQ‐SF, International Consultation on Incontinence Questionnaire‐Short Form; PGI‐I, patient global impression of improvement; PP,
polypropylene; PVDF, polyvinylidene fluoride; UI, urinary incontinence.
aData expressed in median (interquartile range).
TABLE 3 Complications
PP PVDF pa
Intraoperative 7 (5.1%) 4 (2.8%) .356
Bleeding 1 (0.7%) 1 (0.7%)
Vaginal perforation 4 (2.9%) 2 (1.4%)
Other 2 (1.4%) 1 (0.7%)
Early postoperative 25 (18.1%) 22 (15.5%) .452
Temporary elevated PVR 8 (5.8%) 10 (7.0%)
Cystitisb 2 (1.4%) 3 (2.1%)
Suburethral hematoma 2 (1.4%) 1 (0.7%)
Obturator/hypogastric pain 6 (4.3%) 4 (2.8%)
Vaginal exposition 1 (0.7%) 1 (0.7%)
Other 8 (5.8%) 4 (2.8%)
Late postoperative 14 (10.4%) 10 (7.2%) .313
Repeated cystitisb 2 (1.5%) 5 (3.6%)
Voiding dysfunction 1 (0.7%) 1 (0.7%)
Tape extrusion 3 (2.2%) 2 (1.5%)
Obturator/hypogastric pain 7 (5.2%) 2 (1.5%)
Dyspareunia 4 (3.0%) 1 (0.7%)
Sling division 3 (2.2%) 0 (0%) .121
De novo urgency 22 (16.4%) 10 (7.3%) .012
Abbreviations: PP, polypropylene; PVDF, polyvinylidene fluoride; PVR,
post‐void residual urine volume.
aAdjusted p value according to final multivariable models.
bPositive urinary culture.
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observed a higher incidence of de novo UUI in the PP
group. This finding was also observed in our previous
descriptive study,15 and could be explained in part by the
lower elongation and better biocompatibility of PVDF
than PP described in experimental studies.12–14 The
amount of foreign body reaction and the consequent mesh
contraction 13,22 could explain some cases of de novo UUI.
In addition, the overall rates of de novo UUI are similar to
those described previously.15,23 On the contrary, we have
not found the differences in obstructive events observed
previously,15 nor in other complications. However, a
higher number of adverse events that could be associated
with the material used were observed in the PP group,
such as long‐term pain, dyspareunia and the need for sling
division. Although the present study was designed to
compare the effectiveness of the techniques, it is under-
powered to find differences in specific complications due
to the low number of events.
This clinical trial compares these materials obtaining
robust data on their effectiveness as TOT slings. The
objective assessment based on the cough stress test was
limited because it was not performed with a specified
bladder volume, but the effect of this limitation was re-
duced by using a composite outcome based on both ob-
jective and subjective criteria. Another limitation of the
present study is that as it was designed to compare the
effectiveness of the slings, it has not shown enough
power to find differences in complications with low in-
cidence. In addition, some complications may appear
over time and would require a longer follow‐up to be
observed. Therefore, we could not give conclusive results
on the differences in the adverse events. We wish to
highlight that improving the properties of materials used
in urogynecology to enhance their safety while main-
taining their efficacy is an important area of research. In
this regard, PVDF seems to be a good alternative to PP
obtaining similar high cure rates with fewer adverse
events, such as de novo UUI. Despite the fact that PVDF
has shown promising results in this study, there is a
larger experience worldwide with PP slings and therefore
the present results should be taken with caution. Other
studies by different groups are desirable to corroborate or
to refute our clinical findings.
5 | CONCLUSION
We observed a similar high effectiveness with PP and
PVDF TOTs for the treatment of female SUI. PVDF slings
seem to be related with less mesh related adverse events,
such as de novo UUI and pain symptoms, however these
observations should be confirmed in future studies and
on long‐term follow‐up.
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